share_log

Capricor Therapeutics shares are trading higher. The company said it will provide an update on recent findings after a preliminary review of its ongoing open-label extension study of the Phase II HOPE

Capricor Therapeutics shares are trading higher. The company said it will provide an update on recent findings after a preliminary review of its ongoing open-label extension study of the Phase II HOPE

Capricor Treateutics的股價正在上漲。該公司表示,在對其正在進行的第二階段希望的開放標籤延伸研究進行初步審查後,將提供最近發現的最新情況
Benzinga ·  2021/06/17 10:59

Capricor Therapeutics shares are trading higher. The company said it will provide an update on recent findings after a preliminary review of its ongoing open-label extension study of the Phase II HOPE-2 trial with lead asset, CAP-1002 at PPMD 2021.

Capricor Treateutics的股價正在上漲。該公司表示,在對其正在進行的第二階段HOPE-2試驗的開放標籤擴展研究進行初步審查後,它將提供最近發現的最新情況。該試驗採用Lead Asset,CAP-1002,PPMD 2021。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論